Analysts Anticipate Illumina, Inc. (ILMN) Will Post Earnings of $0.69 Per Share

Analysts forecast that Illumina, Inc. (NASDAQ:ILMN) will announce earnings per share of $0.69 for the current quarter, Zacks Investment Research reports. Five analysts have issued estimates for Illumina’s earnings. The highest EPS estimate is $0.72 and the lowest is $0.65. Illumina posted earnings of $0.86 per share during the same quarter last year, which would suggest a negative year-over-year growth rate of 19.8%. The firm is expected to report its next quarterly earnings report on Tuesday, July 25th.

On average, analysts expect that Illumina will report full year earnings of $3.64 per share for the current fiscal year, with EPS estimates ranging from $3.57 to $3.70. For the next fiscal year, analysts anticipate that the company will post earnings of $4.36 per share, with EPS estimates ranging from $4.01 to $4.66. Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side analysts that cover Illumina.

Illumina (NASDAQ:ILMN) last announced its earnings results on Tuesday, April 25th. The life sciences company reported $0.64 earnings per share for the quarter, hitting analysts’ consensus estimates of $0.64. Illumina had a net margin of 19.31% and a return on equity of 22.89%. The business earned $598 million during the quarter, compared to the consensus estimate of $590.51 million. During the same quarter last year, the firm earned $0.71 earnings per share. Illumina’s quarterly revenue was up 4.5% on a year-over-year basis.

ILMN has been the subject of a number of analyst reports. TheStreet upgraded shares of Illumina from a “c+” rating to a “b” rating in a research note on Thursday, April 6th. CL King upgraded shares of Illumina from a “neutral” rating to a “buy” rating in a research note on Friday, January 6th. Bank of America Corp upgraded shares of Illumina from a “neutral” rating to a “buy” rating and raised their price objective for the company from $145.00 to $175.00 in a research note on Tuesday, January 10th. Vetr upgraded shares of Illumina from a “sell” rating to a “buy” rating and set a $175.76 price objective for the company in a research note on Tuesday, January 24th. Finally, Evercore ISI upgraded shares of Illumina from a “hold” rating to a “buy” rating and set a $190.00 price objective for the company in a research note on Monday, February 27th. Three equities research analysts have rated the stock with a sell rating, ten have given a hold rating and eleven have given a buy rating to the company’s stock. Illumina presently has a consensus rating of “Hold” and a consensus target price of $164.70.

In other Illumina news, Director A Blaine Bowman sold 3,000 shares of Illumina stock in a transaction that occurred on Wednesday, February 8th. The shares were sold at an average price of $162.74, for a total transaction of $488,220.00. Following the transaction, the director now owns 16,204 shares of the company’s stock, valued at $2,637,038.96. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Omead Ostadan sold 259 shares of Illumina stock in a transaction that occurred on Monday, January 30th. The shares were sold at an average price of $160.90, for a total transaction of $41,673.10. Following the transaction, the executive vice president now directly owns 27,949 shares in the company, valued at approximately $4,496,994.10. The disclosure for this sale can be found here. Insiders have sold 12,476 shares of company stock worth $2,078,440 in the last ninety days. Insiders own 1.60% of the company’s stock.

Institutional investors have recently modified their holdings of the stock. Forte Capital LLC ADV increased its position in shares of Illumina by 1.6% in the first quarter. Forte Capital LLC ADV now owns 2,185 shares of the life sciences company’s stock valued at $373,000 after buying an additional 35 shares in the last quarter. Gemmer Asset Management LLC increased its position in shares of Illumina by 5.7% in the first quarter. Gemmer Asset Management LLC now owns 686 shares of the life sciences company’s stock valued at $117,000 after buying an additional 37 shares in the last quarter. Concert Wealth Management Inc. increased its position in shares of Illumina by 2.9% in the third quarter. Concert Wealth Management Inc. now owns 1,732 shares of the life sciences company’s stock valued at $315,000 after buying an additional 48 shares in the last quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS increased its position in shares of Illumina by 0.6% in the fourth quarter. Commonwealth of Pennsylvania Public School Empls Retrmt SYS now owns 8,421 shares of the life sciences company’s stock valued at $1,078,000 after buying an additional 48 shares in the last quarter. Finally, Stanford Investment Group Inc. increased its position in shares of Illumina by 5.7% in the fourth quarter. Stanford Investment Group Inc. now owns 1,400 shares of the life sciences company’s stock valued at $179,000 after buying an additional 75 shares in the last quarter. 92.79% of the stock is currently owned by institutional investors and hedge funds.

Shares of Illumina (NASDAQ:ILMN) traded up 0.61% during trading on Thursday, reaching $184.86. 1,083,986 shares of the company were exchanged. The stock has a market capitalization of $26.99 billion, a PE ratio of 37.11 and a beta of 0.79. Illumina has a one year low of $119.37 and a one year high of $186.88. The stock has a 50-day moving average price of $171.90 and a 200-day moving average price of $152.22.

COPYRIGHT VIOLATION NOTICE: “Analysts Anticipate Illumina, Inc. (ILMN) Will Post Earnings of $0.69 Per Share” was posted by Sports Perspectives and is owned by of Sports Perspectives. If you are viewing this article on another site, it was copied illegally and republished in violation of US & international trademark and copyright law. The correct version of this article can be viewed at https://sportsperspectives.com/2017/05/20/analysts-anticipate-illumina-inc-ilmn-will-post-earnings-of-0-69-per-share-updated-updated.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

5 Day Chart for NASDAQ:ILMN

Get a free copy of the Zacks research report on Illumina (ILMN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Illumina Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply